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867-4 Acute Administration of Asymmetric Dimethylarginine 
Reduces Insulin Sensitivity in Mice
Ken Y. Lin, John P. Cooke, Stanford University School of Medicine, Stanford, CA
Background: Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of NO
synthase. ADMA is metabolized by dimethylarginine dimethylaminohydrolase (DDAH).
We have shown that plasma ADMA level inversely correlates with a measure of insulin
sensitivity in humans. We now examine if ADMA reduces insulin sensitivity.
Method: After 4hrs of fasting, wildtype female C57BL/6J mice were injected i.p. with
either ADMA (75mg/kg) or PBS; transgenic mice overexpressing DDAH were given the
same dose of ADMA (n=3 in each group). After 2hrs, insulin was injected and blood glu-
cose was assayed every 5min for 1hr. The half-time of glucose disappearance from
plasma was calculated using a first-order decay model. Plasma ADMA was measured by
HPLC.
Result: Wildtype mice given ADMA showed a delayed and attenuated drop in glucose in
response to insulin compared to those receiving PBS (see figure). Wildtype mice given
ADMA had a significantly higher glucose half-life than those given PBS (47.8±8.5 vs.
20.9±0.4min). Transgenic mice were resistant to the effects of ADMA, and their glucose
half-life was not significantly different from wildtype mice receiving PBS. When given
ADMA, wildtype mice had significantly higher plasma ADMA compared to transgenic
mice (9.2±0.7 vs. 2.9±0.7µM).
Conclusion: Elevated plasma ADMA acutely reduces insulin sensitivity in mice. We
speculate that there is a form of physiological insulin resistance, secondary to ADMA-
induced reduction in skeletal muscle blood flow and glucose disposition.
9:30 a.m.
867-5 Rosiglitazone Modulates Angiogenic Progenitor Cell 
Differentiation and Attenuates Intimal Hyperplasia After 
Vascular Intervention
Chao-Hung Wang, Shu-Hong Li, Richard D. Weisel, Paul E. Szmitko, Cristina Fayet, Ren-
Ke Li, William Stanford, Subodh Verma, Toronto General Hospital, Toronto, ON, Canada
PPAR-γ agonists inhibit vascular smooth muscle proliferation and migration, and improve
endothelial function. It is unknown whether PPAR-γ agonists favorably modulate bone
marrow-derived angiogenic progenitor cells (APCs) to promote endothelial lineage differ-
entiation and early reendothelialization following vascular intervention.
Methods & Results: C57/BL6 mice, treated with or without rosiglitazone (8 mg/kg/day),
a PPAR-γ agonist, underwent femoral angioplasty. Rosiglitazone treatment attenuated
neointimal formation (Intima/Media ratio: 0.98 ± 0.12 rosiglitazone vs. 3.1 ± 0.5 control,
p<0.001, n=10 per group). The contribution of bone marrow-derived cells to neointimal
formation was investigated by bone marrow transplantation from eYFP mice to back-
ground mice. 58±12% of the cells within the neointima at 4 weeks were derived from the
bone marrow. Pure endothelial marker-positive, pure α-smooth muscle actin (αSMA)-
positive, or double-positive APCs could be found in both mouse bone marrow and in
human peripheral blood after culture in conditional medium enriched with VEGF. Rosigli-
tazone caused a 6-fold (p<0.001) increase in colony formation by human endothelial pro-
genitor cells, promoted the differentiation of APCs towards the endothelial lineage in
mouse bone marrow in vivo (from 0.66±0.06% in the control group to 0.95±0.08% in the
rosiglitazone group, p<0.05) and in human peripheral blood in vitro (from 17±2% in the
control group to 42±6% in the rosiglitazone group, p<0.05), and inhibited the differentia-
tion towards the smooth muscle cell lineage. Within the neointima, rosiglitazone also
stimulated APCs to differentiate into mature endothelial cells and caused earlier reendot-
helialization compared to controls (31±5 vs. 8±2 CD31-positive cells per mm of neointi-
mal surface on day 14, p<0.01).Conclusion: Progenitor cells in adult bone marrow and
peripheral blood have different cell fates, being able to develop along hematopoietic,
endothelial, & smooth muscle lineages. Rosiglitazone promotes the differentiation of
APCs towards the endothelial lineage, enhances APC homing to injured vascular sites,
and attenuates restenosis after angioplasty
9:45 a.m.
867-6 Versican Promoter Is a Target for the β-Catenin/Tcf-4 
Signaling Pathway in Vascular Smooth Muscle Cells
Maziar Rahmani, Jon Carthy, Jason T. Read, Zongshu Luo, Mitra Esfandiarei, Paul S. 
Rennie, Bruce M. McManus, University of British Columbia, Vancouver, BC, Canada
Background: Versican (VCN) is one of the proteoglycans constitutively expressed in ath-
erosclerotic lesions. We have investigated the role of the signaling pathways and cis- and
trans-factors in VCN regulation in vascular smooth muscle cells (VSMCs).
Methods and Results: A 752-bp of the human VCN promoter was cloned in luciferase
reporter plasmid (VCN-Luc). PI3K inhibitor LY29004 significantly decreased promoter
activity. Co-transfection of constitutive active- and dominant negative-protein kinase B
(PKB) constructs with VCN-Luc increased and decreased VCN promoter activity. Inhibi-
tion of the glycogen synthase kinase-3β (GSK-3β) activity by LiCl augmented accumula-
tion of β-catenin and induction of promoter activity. β-catenin has no DNA binding domain
therefore it cannot induce transcription of VCN alone. Software analysis revealed a Tcf-4
transcription factor binding site in the VCN promoter. Electrophoretic mobility shift assay
and supershift assay revealed specific binding of recombinant hTcf-4 to this site in the
VCN promoter. In addition, GSK3-β inhibitor LiCl or β-catenin expression vector did not
induce promoter activity when the Tcf-4 binding site was mutated.
Conclusions: Our findings suggest that VCN transcription is predominantly mediated by
activation of PKB and subsequent inhibition of GSK-3β pathway via β-catenin/Tcf-4 tran-
scription factor complex in the VCN promoter in VSMCs. Supported by the Canadian
Institutes of Health Research and the St. Paul’s Hospital Foundation. 
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873-2 Enhanced Pressure Wave Reflection Contributes to Left 
Ventricular Diastolic Dysfunction in Hypertension
Giuseppe Talanas, Pietro Sanna, Davide Pittalis, Pier Sergio Saba, Giuseppina Fiore, 
GianFranco Tola, Barbara Tanda, Antonello Ganau, University of Sassari, Sassari, Italy
Background. Hypertensive left ventricular diastolic dysfunction has been attributed to
intrinsic abnormalities of myocardial relaxation and stiffness. Since relaxation is load-
dependent, it can be affected by changes in afterload due to stronger and earlier
reflected arterial pressure waves (RPWs) caused by hypertension-related aortic stiffen-
ing. Our aim was to analyse relationships of both timing and intensity of RPWs with left
ventricular diastolic function in hypertension.
Methods. We studied 98 untreated uncomplicated hypertensives and 72 healthy controls
We measured left ventricular mass index, isovolumic relaxation time (IRT), peak veloci-
ties of early and late filling and their ratio (E/A) by Doppler-echocardiography. Augmenta-
tion index and transit time of RPWs as percent of ventricular ejection (TT/ET) were
measured on carotid pressure waveforms recorded by applanation tonometry. Aortic stiff-
ness was assessed by aortic pulse wave velocity (PWV).
Results. Hypertensives had significantly higher left ventricular mass (+23%), IRT (+8%),
PWV (+30%) and augmentation index (+185%), and lower E/A (-34%) and TT/ET (-17%)
than controls (p<.01 to .0001). Age and systolic blood pressure were both significantly
